Sep 15, 2026 · 33 min · 10 segments
In this episode, we speak with Dr. Pamela Weiss, pediatric rheumatologist, epidemiologist, and physician-scientist at Children's Hospital of Philadelphia, about axial juvenile spondyloarthritis…
Pamela WeissGuestVicky ShamaganHostClinical trials in juvenile arthritis have been limited, and spondyloarthritis is no exception.
Currently, despite only limited evidence, the recommended therapy for youth with axial spondyloarthritis is TNF inhibition.
However, recent advances are beginning to address some of the critical gaps in the field that have limited research and clinical trials for young people with axial spondyloarthritis.
The manuscript we will discuss today is Measuring the Impact, Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth with Axial Disease.
It was published in Arthritis and Rheumatology, and you can find a link to the manuscript and disclosures in today's show notes.
I'm so pleased to be joined today by the senior author of this study, Dr. Pamela Weiss, who Dr. Weiss earned her BA in molecular biology from Princeton University, her MD from Albert Einstein College of Medicine, and a master's in clinical epidemiology from the University of Pennsylvania.
She completed her pediatric residency and pediatric rheumatology fellowship at the Children's Hospital of Philadelphia, or CHOP.
And she's currently a professor of pediatrics and epidemiology at the Perelman School of Medicine, a senior scholar at the Penn Center for Clinical Epidemiology and Biostatistics, and core faculty with CHOP's Clinical Futures.
And her overarching goal is to improve outcomes by accelerating diagnosis, emphasizing meaningful patient-centered endpoints, and advancing precision medicine.
Dr. Wise's work has earned national recognition through numerous honors, including the Spondyloarthritis Association of America, Bruckle Young Investigator Award, the American College of Rheumatology Kunkel Young Investigator Award, and the ACR Excellence in Investigative Mentoring Award.
And Dr. Weiss is currently serving as the Director of Clinical Research in the Division of Rheumatology at the Children's Hospital of Philadelphia.
So I wondered if you could start us off with a bit of a pediatric primer for those of us who are adult rheumatologists.
Can you tell us about axial spondyloarthritis in children and young adults and what knowledge gaps this study was designed to address?
Read the full transcript.
Create an account to read the whole episode, search across every transcript, and follow the shows you care about.
Clinical trials in juvenile arthritis have been limited, and spondyloarthritis is no exception.
Currently, despite only limited evidence, the recommended therapy for youth with axial spondyloarthritis is TNF inhibition.
However, recent advances are beginning to address some of the critical gaps in the field that have limited research and clinical trials for young people with axial spondyloarthritis.
The manuscript we will discuss today is Measuring the Impact, Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth with Axial Disease.
It was published in Arthritis and Rheumatology, and you can find a link to the manuscript and disclosures in today's show notes.
I'm so pleased to be joined today by the senior author of this study, Dr. Pamela Weiss, who Dr. Weiss earned her BA in molecular biology from Princeton University, her MD from Albert Einstein College of Medicine, and a master's in clinical epidemiology from the University of Pennsylvania.
She completed her pediatric residency and pediatric rheumatology fellowship at the Children's Hospital of Philadelphia, or CHOP.
And she's currently a professor of pediatrics and epidemiology at the Perelman School of Medicine, a senior scholar at the Penn Center for Clinical Epidemiology and Biostatistics, and core faculty with CHOP's Clinical Futures.
And her overarching goal is to improve outcomes by accelerating diagnosis, emphasizing meaningful patient-centered endpoints, and advancing precision medicine.
Dr. Wise's work has earned national recognition through numerous honors, including the Spondyloarthritis Association of America, Bruckle Young Investigator Award, the American College of Rheumatology Kunkel Young Investigator Award, and the ACR Excellence in Investigative Mentoring Award.
And Dr. Weiss is currently serving as the Director of Clinical Research in the Division of Rheumatology at the Children's Hospital of Philadelphia.
So I wondered if you could start us off with a bit of a pediatric primer for those of us who are adult rheumatologists.
Can you tell us about axial spondyloarthritis in children and young adults and what knowledge gaps this study was designed to address?